1. PGEU GPUE Pharmaceutical Group of European Union Groupement Pharmaceutique de l’Union Européenne MHEALTH

2. PGEU GPUE Pharmaceutical Group of European Union Groupement Pharmaceutique de l’Union Européenne Austria Belgium Bulgaria Bosnia Herzegovina Cyprus Czech Rep Denmark Estonia Finland France Germany Greece Hungary Ireland Italy Luxembourg Malta Netherlands Poland Portugal Romania Slovakia Slovenia Spain Sweden United Kingdom Croatia FYR Macedonia Norway Serbia Switzerland Turkey Pharmaceutical Group of European Union Members: Professional Bodies & Pharmacists’ Associations 2014: 32 Countries

3. PGEU GPUE Pharmaceutical Group of European Union Groupement Pharmaceutique de l’Union Européenne

4. PGEU GPUE Pharmaceutical Group of European Union Groupement Pharmaceutique de l’Union Européenne

5. PGEU GPUE Pharmaceutical Group of European Union Groupement Pharmaceutique de l’Union Européenne

6. PGEU GPUE Pharmaceutical Group of European Union Groupement Pharmaceutique de l’Union Européenne Health Apps  IMS study found that just 5 apps account for 15% of market, and two of these are calorie counters;  Half of healthcare apps have only been downloaded 500 times;  The market is overwhelmingly dominated by lifestyle and wellness apps with very few diagnostic or even adherence apps;  There is no evidence [e.g. RCTs] that apps are effective;  There is an inverse relationship between smartphone use and healthcare need. This may change, but not for a long time.

7. PGEU GPUE Pharmaceutical Group of European Union Groupement Pharmaceutique de l’Union Européenne Remote Monitoring

8. PGEU GPUE Pharmaceutical Group of European Union Groupement Pharmaceutique de l’Union Européenne Remote Monitoring  Strong evidence that telemonitoring offers no health benefits over normal care;  Significant problems remain in the area of data transfer and poor adherence – in the NEJM study nearly half trial participants failed to adhere and 14% dropped out immediately;  Chain of Trust study showed that patients and health professionals considered the telehealth agenda to be manufacturer driven.

9. PGEU GPUE Pharmaceutical Group of European Union Groupement Pharmaceutique de l’Union Européenne The Dilemmas of M Health  M Health as a consumer appendage e.g wellness apps is at present a highly marginal phenonemon in terms of overall health service provision, and likely to remain so for the foressable future;  ‘Strong’ M Health (e.g. remote diagnosis and monitoring) needs to break into the mainstream of organised and funded health care. But this is likely to be based on efficiency imperatives, not on patient need, choice or empowerment.  The overall impact of M Health on the technologically incompetent, or averse is unknown, but a case can be made that it will increase health inequalities and undermine social capital.

10. PGEU GPUE Pharmaceutical Group of European Union Groupement Pharmaceutique de l’Union Européenne

11. PGEU GPUE Pharmaceutical Group of European Union Groupement Pharmaceutique de l’Union Européenne THANKYOU THANK YOU www.pgeu.eu